5977 related articles for article (PubMed ID: 3142086)
1. Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site.
Dodd I; Nunn B; Robinson JH
Thromb Haemost; 1988 Jun; 59(3):523-8. PubMed ID: 3142086
[TBL] [Abstract][Full Text] [Related]
2. Isolation and preliminary characterisation of active B-chain of recombinant tissue-type plasminogen activator.
Dodd I; Fears R; Robinson JH
Thromb Haemost; 1986 Feb; 55(1):94-7. PubMed ID: 3085269
[TBL] [Abstract][Full Text] [Related]
3. The use of active centre acylation to control the pharmacokinetic profile of a recombinant chimaeric plasminogen activator.
Wilson S; Cronk DW; Dodd I; Esmail AF; Kalindjian SB; McMurdo L; Browne MJ; Smith RA; Robinson JH
Thromb Haemost; 1993 Dec; 70(6):984-8. PubMed ID: 8165622
[TBL] [Abstract][Full Text] [Related]
4. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.
Bijnens AP; Knockaert I; Cousin E; Kruithof EK; Declerck PJ
Thromb Haemost; 1997 Feb; 77(2):350-6. PubMed ID: 9157595
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
[TBL] [Abstract][Full Text] [Related]
6. [Expression and activity of tissue-type plasminogen activator mutant reteplase with deletion of PAI-1 binding sites].
Zhu MC; Zhan Z; Wang YJ; Liu CG; Shi Y; Cai Q
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Sep; 21(5):565-9. PubMed ID: 16143058
[TBL] [Abstract][Full Text] [Related]
7. The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator.
Lamba D; Bauer M; Huber R; Fischer S; Rudolph R; Kohnert U; Bode W
J Mol Biol; 1996 Apr; 258(1):117-35. PubMed ID: 8613982
[TBL] [Abstract][Full Text] [Related]
8. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
9. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
10. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the fibronectin finger-like domain and the kringle 1 domain.
Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
Thromb Haemost; 1994 Dec; 72(6):893-9. PubMed ID: 7740460
[TBL] [Abstract][Full Text] [Related]
11. On the composition and function of the carbohydrate moiety of tissue-type plasminogen activator from human melanoma cells.
Rijken DC; Emeis JJ; Gerwig GJ
Thromb Haemost; 1985 Dec; 54(4):788-91. PubMed ID: 3937276
[TBL] [Abstract][Full Text] [Related]
12. Elimination of native and carbohydrate-modified tissue plasminogen activator in rabbits.
Einarsson M; Hggroth L; Mattsson C
Thromb Haemost; 1989 Dec; 62(4):1088-93. PubMed ID: 2515604
[TBL] [Abstract][Full Text] [Related]
13. Increased yield of human tissue-type plasminogen activator obtained by means of recombinant DNA technology.
Browne MJ; Dodd I; Carey JE; Chapman CG; Robinson JH
Thromb Haemost; 1985 Aug; 54(2):422-4. PubMed ID: 3936214
[TBL] [Abstract][Full Text] [Related]
14. Some chemical properties of tissue plasminogen activator purified from paranasal mucous membrane.
Kosugi T; Nakamura M; Tsukayama T; Haraguchi S; Noda Y
Rhinology; 1987 Jun; 25(2):129-32. PubMed ID: 3112919
[TBL] [Abstract][Full Text] [Related]
15. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
[TBL] [Abstract][Full Text] [Related]
16. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
17. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver.
Tanswell P; Heinzel G; Greischel A; Krause J
J Pharmacol Exp Ther; 1990 Oct; 255(1):318-24. PubMed ID: 2120422
[TBL] [Abstract][Full Text] [Related]
18. Identification of t-PA as the major active plasminogen activator in human milk.
Marshall JM; Rees MC; Cederholm-Williams SA
Thromb Haemost; 1986 Apr; 55(2):279-81. PubMed ID: 3087004
[TBL] [Abstract][Full Text] [Related]
19. Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain.
Stack MS; Gray RD; Pizzo SV
Cancer Res; 1993 May; 53(9):1998-2004. PubMed ID: 8481902
[TBL] [Abstract][Full Text] [Related]
20. Heparin selectively inhibits synthesis of tissue type plasminogen activator and matrix deposition of plasminogen activator inhibitor 1 by human mesangial cells.
Hagège J; Delarue F; Peraldi MN; Sraer JD; Rondeau E
Lab Invest; 1994 Dec; 71(6):828-37. PubMed ID: 7807964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
